3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Multiple Myeloma
6
Neoplasm Metastasis
4
Carcinoma
4
Breast Neoplasms
4
Neoplasms
3
Melanoma
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Childhood Solid Tumor, Protocol Specific
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Ras-mutated Metastatic Colorectal Cancer
1
Prostatic Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Medulloblastoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Glioblastoma
1
Fibrosarcoma
1
Diffuse Intrinsic Pontine Glioma
1
Interventions
pembrolizumab
23
Nivolumab
22
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Dacarbazine
6
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Biopsy
5
Aminolevulinic Acid
5
encorafenib
4
dabrafenib
4
Photochemotherapy
4
Educational Status
4
trametinib
3
sonidegib
3
montanide ISA 51
3
avelumab
3
Tacrolimus
3
Sodium Chloride
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Skin Neoplasms
×
reolysin
×
Clear all
NCT03282188
2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2
Withdrawn